Pricing Log in Create free account
Friday 6 November 2026 Export SYRE’s income statement to Excel — free account

Spyre Therapeutics, Inc.

SYRE Healthcare Biotechnology

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.

EPS
−624.8%
Free cash flow
−108.8%

Quarter to September 2026, against a year earlier

103.34 6.75 +6.99%
Market cap
$9.2B
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
3/9
Altman Z
−3.82
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Spyre Therapeutics, Inc. 10-K filed Feb 19, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:01 PM ET · Document on sec.gov · Filing index

Red flags

  • Auditor change

    Spyre Therapeutics, Inc. changed auditor from PricewaterhouseCoopers LLP to KPMG LLP

    10-K filed · The filing · sec.gov

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 27, 2025: 110 added · 74 removed · 112 modified; 1 with only figures updated

  1. Modified · Company Overview

    Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company utilizing potential best-in-class antibody engineering, dose optimization, pioneering long-acting antibodies and rational therapeutic antibody combinations to target improved efficacy and convenience in the treatment of redefine the standard of care for inflammatory bowel disease (“IBD”) and other immune-mediatedrheumatic diseases. Spyre’s pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations.